Cite
IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect.
MLA
Benson Jr., Don M., et al. “IPH2101, a Novel Anti-Inhibitory KIR Antibody, and Lenalidomide Combine to Enhance the Natural Killer Cell versus Multiple Myeloma Effect.” Blood, vol. 118, no. 24, Dec. 2011, pp. 6387–91. EBSCOhost, https://doi.org/10.1182/blood-2011-06-360255.
APA
Benson Jr., D. M., Bakan, C. E., Shuhong Zhang, Collins, S. M., Jing Liang, Srivastava, S., Hofmeister, C. C., Efebera, Y., Andre, P., Romagne, F., Bléry, M., Bonnafous, C., Jianying Zhang, Clever, D., Caligiuri, M. A., & Farag, S. S. (2011). IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect. Blood, 118(24), 6387–6391. https://doi.org/10.1182/blood-2011-06-360255
Chicago
Benson Jr., Don M., Courtney E. Bakan, Shuhong Zhang, Shauna M. Collins, Jing Liang, Shivani Srivastava, Craig C. Hofmeister, et al. 2011. “IPH2101, a Novel Anti-Inhibitory KIR Antibody, and Lenalidomide Combine to Enhance the Natural Killer Cell versus Multiple Myeloma Effect.” Blood 118 (24): 6387–91. doi:10.1182/blood-2011-06-360255.